Interferons and multiple sclerosis: Is it plausible that β-IFN treatment could influence the risk of cancer among MS patients?

Expert Review of Neurotherapeutics

Volumn 9, Issue 9, 2009, Pages 1263-1265

  Kingwell, Elaine ^a   Tremlett, Helen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GLATIRAMER; INTERFERON; MITOXANTRONE;

CANCER RISK; DRUG EFFECT; EDITORIAL; HUMAN; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS;

COMORBIDITY; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; NEOPLASMS; RISK ASSESSMENT;

EID: 70349439271     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.76     Document Type: Editorial

References (27)

1. Coles A. Multiple sclerosis. Pract. Neurol. 9, 118-126 (2009). • Overview of the epidemiology, features, diagnosis, management and treatment of multiple sclerosis (MS).
2. Yong VW. Differential mechanisms of action of interferon-β and glatiramer aetate in MS. Neurology 59, 802-808 (2002).
3. Satoh J, Nanri Y, Tabunoki H, Yamamura T. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNβ-related adverse effects in multiple sclerosis. BMC Neurol. 6, 18 (2006). (Pubitemid 43984041)
4. Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. Second-generation interferons for cancer: clinical targets. Semin. Cancer Biol. 10, 125-144 (2000). (Pubitemid 30458473)
5. Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman JW. Increased incidence of second neoplasms in patients treated with interferon α 2b for hairy cell leukemia: a clinicopathologic assessment. Blood 83, 2931-2938 (1994). (Pubitemid 24142726)
6. Roy L, Guilhot J, Martineau G, Larchee R, Guilhot F. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 19, 1689-1692 (2005). (Pubitemid 43090424)
7. Sieja KS, Everson GT. De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy. Dig. Dis. Sci. 51, 600-602 (2006).
8. Lakatos PL, Fekete S, Horanyi M, Fischer S, Abonyi ME. Development of multiple myeloma in a patient with chronic hepatitis C: a case report and review of the literature. World J. Gastroenterol. 12, 2297-2300 (2006).
9. Eggermont AM, Suciu S, MacKie R et al. Post-surgery adjuvant therapy with intermediate doses of interferon α 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366, 1189-1196 (2005). (Pubitemid 41393597)
10. Dienstag JL, McHutchison JG. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology 130, 225-230 (2006).
11. Freedman MS, Patry DG, Grand'Maison F, Myles ML, Paty DW, Selchen DH. Treatment optimization in multiple sclerosis. Can. J. Neurol. Sci. 31, 157-168 (2004).
12. Barbero P, Verdun E, Bergui M et al. High-dose, frequently administered interferon β therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the Interferon b Dose- Reduction Study. J. Neurol. Sci. 222, 13-19 (2004). (Pubitemid 38881501)
13. Batay F, Al Mefty O. Growth dynamics of meningiomas in patients with multiple sclerosis treated with interferon: report of two cases. Acta Neurochir. (Wien) 144, 365-368 (2002). (Pubitemid 34507858)
14. Sega S, Horvat A, Popovic M. Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-β treated multiple sclerosis patients. Report of two cases. Clin. Neurol. Neurosurg. 108, 259-265 (2006). (Pubitemid 43319524)
15. Gibbs, E, Tremlett H, Ball N, Hashimoto S. Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-β. Eur. J. Neurol. 15, E4 (2008). (Pubitemid 350265274)
16. Drevelegas A, Xinou E, Karacostas D, Parissis D, Karkavelas G, Milonas I. Meningioma growth and interferon β-1b treated multiple sclerosis: coincidence or relationship? Neuroradiology 47, 516-519 (2005). • Case report suggesting that β-IFN treatment was associated with progression of meningioma in MS, causing the authors to speculate that treatment may have enhanced PDGF on the tumor, or downregulated TGF receptors, resulting in tumor growth.
17. Lebrun C, Debouverie M, Vermersch P et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult. Scler. 14, 399-405 (2008). • Study of cancer risk in MS comparing the risk in untreated patients with those exposed to immunomodulatory therapies or immunosuppressants. Compared with untreated patients, women exposed to immunosuppressants had an elevated risk of breast cancer and all cancer risk increased with extended treatment exposure to both types of therapy. (Pubitemid 351676435)
18. Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology 72, 1170-1177 (2009). • Large population-based study of patients with a hospital discharge diagnosis of MS showing a decreased risk of nonbenign cancer; adjustments were made for socioeconomic status. Risk of cancer in parents of MS patients was comparable to the general population risk indicating that genetic protection against cancer in MS might not explain the reduced risk of cancer in MS.
19. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish multiple sclerosis registry. J. Neurol. Neurosurg. Psychiatr. 65, 56-59 (1998). (Pubitemid 28302357)
20. Achiron A, Barak Y, Gail M et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res. Treat. 89, 265-270 (2005). (Pubitemid 43293074)
21. Nielsen NM, Rostgaard K, Rasmussen S et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int. J. Cancer 118, 979-984 (2006). (Pubitemid 43157674)
22. Goldacre MJ, Seagroatt V, Yeates D, Acheson ED. Skin cancer in people with multiple sclerosis: a record linkage study. J. Epidemiol. Community Health 58, 142-144 (2004).
23. Midgard R, Glattre E, Gronning M, Riise T, Edland A, Nyland H. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol. Scand. 93, 411-415 (1996). (Pubitemid 26232751)
24. Warren S, Warren KG. Multiple sclerosis and associated diseases: a relationship to diabetes mellitus. Can. J. Neurol. Sci. 8, 35-39 (1981). (Pubitemid 11096741)
25. Wynn DR, Rodriguez M, O'Fallon WM, Kurland LT. A reappraisal of the epidemiology of multiple sclerosis in olmsted county, Minnesota. Neurology 40, 780-786 (1990). (Pubitemid 20159613)
26. Sumelahti ML, Pukkala E, Hakama M. Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology 23, 224-227 (2004). (Pubitemid 39179151)
27. Sumelahti ML, Tienari PJ, Wikstrom J, Salminen TM, Hakama M. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult. Scler. 8, 350-355 (2002).